Abstract:Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated disease of the peripheral nervous system. The main clinical manifestations are symmetrical weakness and sensory dysfunction in the proximal and distal limbs. The course of the disease often presents as chronic progression or remission recurrence, seriously affecting the physical and mental health of patients. [ 1 , 2 ] At present, the factors triggering the onset and progression of CIDP are not clear, and treatment methods aim to suppress potential immunopathology. [ 3 ] Glucocorticoids (GC), intravenous immunoglobulins (IVIG), and plasma exchange (PE) are the first-line therapies. Immunosuppressive or immunomodulatory drugs, such as azathioprine, mycophenolate mofetil (MMF), and rituximab, are adjunctive drugs chosen to reduce the dosage of first-line drugs. When first-line drugs are ineffective, they can also serve as substitutes. [ 4 ] Nocardiosis is a rare and destructive opportunistic disease that tends to occur in patients with impaired immune function. [ 5 ] Here, we report a case of CIDP combined with pulmonary nocardiosis and, for the first time, link these 2 diseases together. It is worth noting that in order to avoid the progression and recurrence of CIDP, we did not stop using immunomodulatory drugs during the treatment process. Despite this, the patient condition worsened when lung inflammation improved, leading to persistent respiratory failure and ultimately death. Treatment contradictions, medication issues, and patient compliance issues reflected in this case are worth considering.

Chronic inflammatory demyelinating polyneuropathy with pulmonary nocardiosis: A case report